Valspodar

Drug Profile

Valspodar

Alternative Names: Amdray; PSC 833; SDZ PSC 833

Latest Information Update: 12 Sep 2001

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Class Antineoplastics
  • Mechanism of Action P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Breast cancer; Cancer; Multiple myeloma; Ovarian cancer; Renal cancer

Most Recent Events

  • 12 Sep 2001 A phase I/II trial has been added to the pharmacokinetics and Cancer therapeutic trials sections
  • 19 Apr 2001 Discontinued-II for Breast cancer in USA (PO)
  • 19 Apr 2001 Discontinued-II for Renal cancer in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top